CRON vs. WEED, ACB, GUD, TLRY, BHC, DNTL, SIA, WELL, EXE, and OGI
Should you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include Canopy Growth (WEED), Aurora Cannabis (ACB), Knight Therapeutics (GUD), Tilray Brands (TLRY), Bausch Health Companies (BHC), dentalcorp (DNTL), Sienna Senior Living (SIA), WELL Health Technologies (WELL), Extendicare (EXE), and Organigram (OGI). These companies are all part of the "medical" sector.
Cronos Group (TSE:CRON) and Canopy Growth (TSE:WEED) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.
In the previous week, Canopy Growth had 2 more articles in the media than Cronos Group. MarketBeat recorded 5 mentions for Canopy Growth and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.52 beat Canopy Growth's score of 0.46 indicating that Cronos Group is being referred to more favorably in the media.
13.1% of Cronos Group shares are owned by institutional investors. Comparatively, 4.9% of Canopy Growth shares are owned by institutional investors. 46.6% of Cronos Group shares are owned by insiders. Comparatively, 19.0% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Cronos Group has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.
Cronos Group presently has a consensus target price of C$2.77, indicating a potential downside of 28.97%. Canopy Growth has a consensus target price of C$3.20, indicating a potential downside of 76.28%. Given Cronos Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe Cronos Group is more favorable than Canopy Growth.
Canopy Growth received 571 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 62.44% of users gave Canopy Growth an outperform vote while only 51.11% of users gave Cronos Group an outperform vote.
Canopy Growth has a net margin of 0.00% compared to Cronos Group's net margin of -84.78%. Cronos Group's return on equity of -6.30% beat Canopy Growth's return on equity.
Cronos Group has higher earnings, but lower revenue than Canopy Growth. Cronos Group is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Summary
Cronos Group beats Canopy Growth on 10 of the 17 factors compared between the two stocks.
Get Cronos Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cronos Group Competitors List
Related Companies and Tools
